摘要:
A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X− is an anion with a single negative charge; and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.
摘要:
A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X− is an anion with a single negative charge; and (b) a betamimetic 2, or a solvate or hydrate thereof, optionally in the form of the enantiomers, mixtures of the enantiomers, or in the form of the racemates thereof, processes for preparing them and their use in the treatment of respiratory complaints.
摘要:
A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X− is an anion with a single negative charge; and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.
摘要:
A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X− is an anion with a single negative charge; and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.
摘要:
The present invention relates to new anticholinergics of general formula 1 wherein A, X−, and the groups R1, R2, R3, R4, R5, R6 and R7 may have the meanings given in the claims and in the specification, processes for preparing them and their use as pharmaceutical compositions.
摘要:
The present invention relates to new anticholinergics of general formula 1 wherein A, X−, and the groups R1, R2, R3, R4, R5, R6 and R7 may have the meanings given in the claims and in the specification, processes for preparing them and their use as pharmaceutical compositions.
摘要:
The present invention relates to new anticholinergics of general formula 1: wherein A, X− and the groups R1, R2, R3, R4, R5, R6 and R7 may have the meanings given in the claims and in the specification, processes for preparing them and their use as pharamaceutical compositions.
摘要:
On account of the surprisingly powerful and long-lasting effect thereof, the salts of the L-(−)-enantiomer of (endo, syn)-(−)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(methylethyl)-8-azoniabicyclo [3,2,1]octane are suitable as active substances for drugs administered by inhalation for respiratory tract therapy.
摘要:
Crystalline monohydrate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.
摘要:
A method of making a physically stable and homogenous powdered pharmaceutical composition comprising a tiotropium salt and a physiologically acceptable excipient, the method comprising: (a) suspending the tiotropium salt and the physiologically acceptable excipient in a suspending agent in which the tiotropium salt and the physiologically acceptable excipient are essentially insoluble to obtain a suspension; and (b) removing the suspending agent from the suspension of step (a) to obtain the pharmaceutical composition, the pharmaceutical composition itself, and method of treating respiratory diseases, especially chronic obstructive pulmonary disease and asthma, in a patient in need thereof by administering an effective amount of the pharmaceutical composition to the patient.